Use of the Slow-Delivery Platform, VacSIM, Shapes the Host Immune Response to Increase Protection Against Influenza Infection.

Anna L McCormick, Ted M Ross, Donald A Harn, Jarrod J Mousa

Abstract read

In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anna L McCormickCenter for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.

Ted M RossCenter for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0003-1947-7469

Donald A HarnDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.

Jarrod J MousaCenter for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0003-4709-2478

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025

$74.6M

NIAID NIH HHS 75N93019C00052NIAID NIH HHS 75N93019C00052-P00024-9999-1

6 · The paper itself

Abstract

Influenza virus is a leading cause of global morbidity and mortality due to acute lower respiratory infection, even with the widespread use of multiple licensed influenza vaccines. However, antigenic drift during influenza replication can cause vaccine-induced antibodies to poorly neutralize influenza virus, thereby reducing vaccine effectiveness. To help overcome this problem, we leveraged a hydrogel platform with influenza hemagglutinin (HA) protein to induce prolonged antigen exposure. The hydrogel platform, Vaccine Self-Assembling Immune Matrix (VacSIM

Indexed as

Hemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsAntibodies, ViralFemaleHumansHydrogelsInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanLungMiceMice, Inbred BALB CVaccinationAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHydrogelsInfluenza VaccinesantibodyCOBRAhemagglutinininfluenzaslow-deliveryvaccine

Identifiers

PMID41012618

DOI10.3390/v17091190

PMCPMC12474215

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.